Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
01 Mar 2020
Historique:
received: 01 07 2019
accepted: 04 02 2020
entrez: 2 3 2020
pubmed: 3 3 2020
medline: 22 9 2020
Statut: epublish

Résumé

Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. Based on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs. Efficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study. A single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose.

Sections du résumé

BACKGROUND BACKGROUND
Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs.
METHODS METHODS
Based on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs.
RESULTS RESULTS
Efficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study.
CONCLUSIONS CONCLUSIONS
A single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose.

Identifiants

pubmed: 32113466
doi: 10.1186/s13071-020-3944-3
pii: 10.1186/s13071-020-3944-3
pmc: PMC7049393
doi:

Substances chimiques

Acaricides 0
Azetidines 0
Drug Combinations 0
Macrolides 0
Spiro Compounds 0
sarolaner 0
Pyrantel 4QIH0N49E7
moxidectin NGU5H31YO9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

57

Références

Trends Parasitol. 2012 Jul;28(7):267-79
pubmed: 22627116
J Clin Microbiol. 1996 Aug;34(8):1952-6
pubmed: 8818889
Vet Parasitol. 2013 May 1;194(1):84-97
pubmed: 23741753
Vet Microbiol. 2013 Apr 12;163(1-2):97-102
pubmed: 23290118
Vet Parasitol. 2009 Aug 26;163(4):298-305
pubmed: 19403239
Chem Res Toxicol. 2013 Apr 15;26(4):514-6
pubmed: 23465072
Vet Parasitol. 1989 Nov;34(1-2):117-22
pubmed: 2588462
Annu Rev Entomol. 1997;42:451-73
pubmed: 9017899
Vet Clin North Am Small Anim Pract. 2009 Nov;39(6):1173-200, viii
pubmed: 19932369
Trends Parasitol. 2005 May;21(5):232-6
pubmed: 15837612
Insects. 2017 Oct 27;8(4):
pubmed: 29077073
Clin Microbiol Rev. 2000 Jul;13(3):428-38
pubmed: 10885985
Trends Parasitol. 2010 Apr;26(4):155-61
pubmed: 20172762
Emerg Infect Dis. 2008 Jul;14(7):1019-23
pubmed: 18598619
Med Vet Entomol. 2009 Sep;23(3):187-94
pubmed: 19712149
Vet Parasitol. 2016 May 30;222:3-11
pubmed: 26961590
Vet Dermatol. 2009 Oct;20(5-6):435-40
pubmed: 20178481

Auteurs

Kristina Kryda (K)

Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA. kristina.a.kryda@zoetis.com.

Sean P Mahabir (SP)

Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.

Lori Carter (L)

Stillmeadow, Inc., 12852 Park One Drive, Sugar Land, TX, 77478, USA.

William R Everett (WR)

BerTek, Inc., PO Box 606, Greenbrier, AR, 72058, USA.

David R Young (DR)

Young Veterinary Research Services, Inc. (YVRS), 7243 East Ave, Turlock, CA, 95380, USA.

Leon Meyer (L)

Clinvet International (Pty) Ltd, Uitsigweg, Bainsvlei, Bloemfontein, 9338, Republic of South Africa.

Mirjan Thys (M)

Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, 1930, Zaventem, Belgium.

Sara Chapin (S)

Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.

Susan J Holzmer (SJ)

Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.

Csilla Becskei (C)

Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, 1930, Zaventem, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH